| CorMedix Inc. to Participate in the RBC Global Healthcare Conference |
BERKELEY HEIGHTS, N.J., May 15, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, will be participating in the RBC Capital Markets Global Healthcare Conference, taking place in New York on May 20-21, 2025. |
globenewswire.com |
2025-05-15 12:30:00 |
Czytaj oryginał (ang.) |
| Surging Earnings Estimates Signal Upside for CorMedix (CRMD) Stock |
CorMedix (CRMD) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions. |
zacks.com |
2025-05-09 17:20:37 |
Czytaj oryginał (ang.) |
| CorMedix, Inc. (CRMD) Q1 2025 Earnings Call Transcript |
CorMedix, Inc. (NASDAQ:CRMD ) Q1 2025 Earnings Conference Call May 6, 2025 8:30 AM ET Company Participants Dan Ferry – LifeSci Advisors Joe Todisco – Chief Executive Officer Matt David – Executive Vice President and Chief Financial Officer Liz Hurlburt – Executive Vice President, Chief Clinical Strategy and Operations Officer Conference Call Participants Gregory Renza – RBC Capital Roana Ruiz – Leerink Partners Leszek Sulewski – Truist Securities Serge Belanger – Needham & Company Operator Good day and welcome to the CorMedix, Inc. First Quarter 2025 Financial Results Conference Call. All participants will be in listen-only mode. |
seekingalpha.com |
2025-05-06 15:59:18 |
Czytaj oryginał (ang.) |
| CorMedix (CRMD) Surpasses Q1 Earnings and Revenue Estimates |
CorMedix (CRMD) came out with quarterly earnings of $0.30 per share, beating the Zacks Consensus Estimate of $0.25 per share. This compares to loss of $0.25 per share a year ago. |
zacks.com |
2025-05-06 13:41:05 |
Czytaj oryginał (ang.) |
| CorMedix Inc. Reports First Quarter 2025 Financial Results and Provides Business Update |
‒ Q1 2025 Net Revenue of $39.1mm; Adjusted EBITDA of $23.6mm ‒ Conference Call Scheduled for Today at 8:30 a.m. Eastern Time BERKELEY HEIGHTS, NJ. |
globenewswire.com |
2025-05-06 11:30:00 |
Czytaj oryginał (ang.) |
| CorMedix Inc. to Report First Quarter 2025 Financial Results and Provide a Corporate Update on May 6, 2025 |
BERKELEY HEIGHTS, N.J., April 29, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that it will report its financial results for the first quarter ended March 31, 2025, before the market opens on Tuesday, May 6, 2025, and will host a corporate update conference call at 8:30am Eastern Time. |
globenewswire.com |
2025-04-29 12:30:00 |
Czytaj oryginał (ang.) |
| Cormedix Inc. Announces Preliminary First Quarter 2025 Results and Raises H1 2025 Net Sales Guidance |
‒ Q1 2025 Unaudited Net Revenue of $39.0 million ‒ ‒ Expected Q1 Adjusted EBITDA above $22.5 million ‒ ‒ Q1 2025 Cash and Cash Equivalents of Approximately $77.5 million ‒ BERKELEY HEIGHTS, N.J., April 08, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announces its preliminary unaudited first quarter results and provides an update on its business. |
globenewswire.com |
2025-04-08 11:30:00 |
Czytaj oryginał (ang.) |
| CorMedix Inc. to Participate in the 24th Annual Needham Virtual Healthcare Conference |
BERKELEY HEIGHTS, N.J., April 02, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that management will be participating in the 24th Annual Needham Virtual Healthcare Conference, taking place virtually on April 7-10, 2025. |
globenewswire.com |
2025-04-02 12:30:00 |
Czytaj oryginał (ang.) |
| An Investigation Has Commenced on Behalf of CorMedix Inc. Shareholders. Contact Levi & Korsinsky to Discuss your CRMD Losses. |
NEW YORK, NY / ACCESS Newswire / April 2, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of CorMedix Inc. ("CorMedix Inc.") (NASDAQ:CRMD) concerning possible violations of federal securities laws. Cormedix reported fourth quarter and full year 2024 financial results. |
accessnewswire.com |
2025-04-02 11:25:00 |
Czytaj oryginał (ang.) |
| CorMedix Inc. (CRMD) Investors with Losses are Urged to Contact Levi & Korsinsky to Discuss Their Rights |
NEW YORK, NY / ACCESS Newswire / April 1, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of CorMedix Inc. ("CorMedix Inc.") (NASDAQ:CRMD) concerning possible violations of federal securities laws. Cormedix reported fourth quarter and full year 2024 financial results. |
accessnewswire.com |
2025-04-01 11:25:00 |
Czytaj oryginał (ang.) |
| CRMD ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by CorMedix Inc. |
NEW YORK, NY / ACCESS Newswire / March 31, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of CorMedix Inc. ("CorMedix Inc.") (NASDAQ:CRMD) concerning possible violations of federal securities laws. Cormedix reported fourth quarter and full year 2024 financial results. |
accessnewswire.com |
2025-03-31 11:25:00 |
Czytaj oryginał (ang.) |
| CorMedix: A Fair-Priced Biotech Company With A Bright Future |
CorMedix Inc.'s DefenCath, FDA-approved in Q4 2023, effectively prevents catheter-related bloodstream infections in hemodialysis patients, showing 71% efficacy compared to competitors. Despite recent profitability and strong market potential, the stock price has increased post-FDA approval, making it appropriately priced for its risk level. Key risks include adoption speed, supply chain scalability, and regulatory changes; maintaining relationships with major dialysis operators is crucial. |
seekingalpha.com |
2025-03-28 05:01:03 |
Czytaj oryginał (ang.) |
| CorMedix Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - CRMD |
NEW YORK, NY / ACCESS Newswire / March 27, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of CorMedix Inc. ("CorMedix Inc.") (NASDAQ:CRMD) concerning possible violations of federal securities laws. Cormedix reported fourth quarter and full year 2024 financial results. |
accessnewswire.com |
2025-03-27 23:15:00 |
Czytaj oryginał (ang.) |
| CORMEDIX ALERT: Bragar Eagel & Squire, P.C. is Investigating CorMedix Inc. on Behalf of CorMedix Stockholders and Encourages Investors to Contact the Firm |
NEW YORK, March 27, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against CorMedix Inc. (“CorMedix” or the “Company”) (NASDAQ: CRMD) on behalf of CorMedix stockholders. Our investigation concerns whether CorMedix has violated the federal securities laws and/or engaged in other unlawful business practices. |
globenewswire.com |
2025-03-27 23:00:00 |
Czytaj oryginał (ang.) |
| Lost Money on CorMedix Inc.(CRMD)? Contact Levi & Korsinsky Regarding an Ongoing Investigation |
NEW YORK, NY / ACCESS Newswire / March 26, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of CorMedix Inc. ("CorMedix Inc.") (NASDAQ:CRMD) concerning possible violations of federal securities laws. Cormedix reported fourth quarter and full year 2024 financial results. |
accessnewswire.com |
2025-03-26 21:15:00 |
Czytaj oryginał (ang.) |
| CorMedix Inc. (CRMD) Shareholders May Have Been Affected by Fraud- Levi & Korsinsky Investigates |
NEW YORK, NY / ACCESS Newswire / March 26, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of CorMedix Inc. ("CorMedix Inc.") (NASDAQ:CRMD) concerning possible violations of federal securities laws. Cormedix reported fourth quarter and full year 2024 financial results. |
accessnewswire.com |
2025-03-26 16:45:00 |
Czytaj oryginał (ang.) |
| INVESTOR ALERT: Investigation of CorMedix Inc. (CRMD) Announced by Holzer & Holzer, LLC |
ATLANTA, March 25, 2025 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether CorMedix Inc. (“CorMedix” or the “Company”) (NASDAQ: CRMD) complied with federal securities laws. On March 25, 2025, Cormedix reported fourth quarter and full year 2024 financial results. During the Company's earnings call held the same day, Cormedix noted that “we do expect to begin to see some net price erosion beginning in the second quarter of 2025.” Following this news, the price of the Company's stock dropped. |
globenewswire.com |
2025-03-25 19:06:00 |
Czytaj oryginał (ang.) |
| CorMedix Inc. (CRMD) Q4 2024 Earnings Call Transcript |
CorMedix Inc. (NASDAQ:CRMD ) Q4 2024 Earnings Conference Call March 25, 2025 8:30 AM ET Company Participants Dan Ferry - Managing Director, LifeSci Advisors Joe Todisco - Chief Executive Officer Matt David - Executive Vice President and Chief Financial Officer Erin Mistry - Executive Vice President and Chief Commercial Officer Liz Hurlburt - Executive Vice President, Chief Clinical Strategy and Operations Officer Conference Call Participants Roanna Ruiz - Leerink Partners Jason Butler - Citizens JMP Anish Nikhanj - RBC Capital Markets Jeevan Larson - Truist Securities John Todaro - Needham & Company Operator Good day and welcome to the CorMedix Inc. Fourth Quarter and Full Year 2024 Financial Results Conference Call. All participants will be in listen-only mode. |
seekingalpha.com |
2025-03-25 12:51:56 |
Czytaj oryginał (ang.) |
| CorMedix (CRMD) Q4 Earnings and Revenues Beat Estimates |
CorMedix (CRMD) came out with quarterly earnings of $0.22 per share, beating the Zacks Consensus Estimate of $0.17 per share. This compares to loss of $0.26 per share a year ago. |
zacks.com |
2025-03-25 11:40:23 |
Czytaj oryginał (ang.) |
| CorMedix Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update |
‒ Q4 2024 Net Revenue of $31.2mm; 2024 Net Revenue of $43.5mm ‒ ‒ Q4 Net Income of $13.5mm and Adjusted EBITDA of $15.3mm ‒ ‒ Conference Call Scheduled for Today at 8:30 a.m. Eastern Time ‒ BERKELEY HEIGHTS, N.J. |
globenewswire.com |
2025-03-25 09:30:00 |
Czytaj oryginał (ang.) |
| CorMedix Stock Rises on Q4 Preliminary Sales Beating Estimates |
CRMD reports $31 million in preliminary sales from its sole marketed product in Q4, surpassing its previous guidance of breaking even by 2024. |
zacks.com |
2025-01-08 16:42:13 |
Czytaj oryginał (ang.) |
| CorMedix Inc. Announces Preliminary Fourth Quarter 2024 Results and Provides Business Update |
‒ Q4 2024 Unaudited Net Revenue of Approximately $31mm ‒ ‒ FY 2024 Unaudited Net Revenue of Approximately $43mm ‒ ‒ Expects Q4 Adjusted EBITDA to Exceed $12mm ‒ BERKELEY HEIGHTS, N.J., Jan. 07, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announces its preliminary unaudited fourth quarter results and provides an update on its business. |
globenewswire.com |
2025-01-07 09:30:00 |
Czytaj oryginał (ang.) |
| Is CorMedix (CRMD) Stock Outpacing Its Medical Peers This Year? |
Here is how CorMedix (CRMD) and ResMed (RMD) have performed compared to their sector so far this year. |
zacks.com |
2024-12-27 12:41:20 |
Czytaj oryginał (ang.) |
| CorMedix Inc. Added to Nasdaq Biotechnology Index |
BERKELEY HEIGHTS, N.J., Dec. 19, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced it will be added to the Nasdaq Biotechnology Index (Nasdaq: NBI) (the “NBI”). CorMedix's addition to the NBI will become effective prior to the market open on Monday, December 23, 2024. |
globenewswire.com |
2024-12-19 10:30:00 |
Czytaj oryginał (ang.) |
| CorMedix Inc. Supports CMS Policy Updates Regarding Access to Innovative Drug Products |
BERKELEY HEIGHTS, N.J., Nov. 26, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today highlights key policy changes from CMS that benefit hemodialysis patients. Yesterday, the Centers for Medicare & Medicaid Services (CMS) and the Center for Medicare and Medicaid Innovation (CMMI) released important policy updates that will broaden the access of Medicare patients managing End Stage Renal Disease (ESRD) and on dialysis to innovative new therapies. |
globenewswire.com |
2024-11-26 10:30:00 |
Czytaj oryginał (ang.) |
| CorMedix (CRMD) Upgraded to Strong Buy: What Does It Mean for the Stock? |
CorMedix (CRMD) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
zacks.com |
2024-11-08 15:01:25 |
Czytaj oryginał (ang.) |
| Best Momentum Stocks to Buy for November 8th |
CRMD, FFIC and SPPJY made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on November 8, 2024. |
zacks.com |
2024-11-08 13:15:25 |
Czytaj oryginał (ang.) |
| Stock Picks From Seeking Alpha's October 2024 New Analysts |
In October, 42 new analysts joined Seeking Alpha, sharing diverse investment ideas and strategies, from biotech to real estate. Highlighted strong buy recommendations include MicroStrategy, CorMedix, Hewlett Packard Enterprise, Vertex Pharmaceuticals, and several others. Readers are encouraged to engage with the new analysts, share thoughts on their picks, and join the conversation. |
seekingalpha.com |
2024-11-08 10:00:00 |
Czytaj oryginał (ang.) |
| New Strong Buy Stocks for November 8th |
SPPJY, FFIC, CRMD, NTGR and AACAY have been added to the Zacks Rank #1 (Strong Buy) List on November 8, 2024. |
zacks.com |
2024-11-08 09:16:08 |
Czytaj oryginał (ang.) |
| Wall Street Analysts See a 52.15% Upside in CorMedix (CRMD): Can the Stock Really Move This High? |
The consensus price target hints at a 52.2% upside potential for CorMedix (CRMD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. |
zacks.com |
2024-11-04 12:55:29 |
Czytaj oryginał (ang.) |
| CorMedix Inc. to Participate in the Truist Securities BioPharma Symposium |
BERKELEY HEIGHTS, N.J., Nov. 04, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that management will be participating in the Truist Securities BioPharma Symposium, taking place in New York City on Thursday, November 7, 2024. |
globenewswire.com |
2024-11-04 10:30:00 |
Czytaj oryginał (ang.) |
| CorMedix Inc. (CRMD) Q3 2024 Earnings Call Transcript |
CorMedix Inc. (NASDAQ:CRMD ) Q3 2024 Earnings Call October 30, 2024 8:30 AM ET Company Participants Dan Ferry - Investor Relations Joe Todisco - Chief Executive Officer Matt David - Executive Vice President and Chief Financial Officer Beth Zelnick Kaufman - Executive Vice President and Chief Legal Officer Liz Hulburt - Executive Vice President and Chief Clinical Strategy and Operations Officer Erin Mistry - Executive Vice President and Chief Commercial Officer Conference Call Participants Jason Butler - Citizens JMP Gregory Renza - RBC Capital Brandon Folkes - Rodman & Renshaw Les Sulewski - Truist Securities Serge Belanger - Needham & Company Operator Good day and welcome to the CorMedix Inc. Third Quarter 2024 Financial Results Conference Call. [Operator Instructions] Please note this event is being recorded. |
seekingalpha.com |
2024-10-30 14:32:08 |
Czytaj oryginał (ang.) |
| CorMedix (CRMD) Reports Q3 Loss, Tops Revenue Estimates |
CorMedix (CRMD) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.10. This compares to loss of $0.17 per share a year ago. |
zacks.com |
2024-10-30 11:40:26 |
Czytaj oryginał (ang.) |
| CorMedix Inc. Reports Third Quarter and Nine Month 2024 Financial Results and Provides Business Update |
‒ Q3 2024 Net Revenue of $11.5 million ‒ ‒ Commercializing DefenCath with Four of Top Five US Dialysis Providers ‒ ‒ Conference Call Scheduled for Today at 8:30 a.m. Eastern Time ‒ BERKELEY HEIGHTS, N.J. |
globenewswire.com |
2024-10-30 09:30:00 |
Czytaj oryginał (ang.) |
| CorMedix 2.0: New Leadership, New Approval, New Focus |
CorMedix is a biopharmaceutical company that has undergone a re-birth as it enters a new phase with FDA approval of its anti-infective catheter solution, DefenCath. The company has faced challenges in the past, including management issues and regulatory delays, but now warrants a fresh look and valuation as the company executes on commercialization. DefenCath offers a unique solution for preventing catheter-related bloodstream infections, with the potential to reduce costs and save lives. |
seekingalpha.com |
2024-10-28 15:33:43 |
Czytaj oryginał (ang.) |
| Undercovered Dozen: CorMedix, Cabaletta, Skyx Platforms, Dynex Capital + |
The 'Undercovered' Dozen highlights 12 lesser-covered stock ideas from October 18th - 24th, offering fresh investment takes for community discussion. Dnis Buivolov updates their Nebius Group valuation; core business Nebius AI targets a $260 billion market by 2030, driven by AI infrastructure demand. ASP Isotopes' breakthrough in Ytterbium-176 enrichment positions it as a key supplier in high-margin radiopharmaceutical and nuclear fuel markets according to Sean Daly. |
seekingalpha.com |
2024-10-25 18:30:53 |
Czytaj oryginał (ang.) |
| CorMedix Inc. Announces New Data at ASN Kidney Week 2024 |
Study highlights significant healthcare challenges and costs associated with bloodstream infections (BSIs) in patients receiving chronic hemodialysis through central venous catheters (HD-CVCs) Study highlights significant healthcare challenges and costs associated with bloodstream infections (BSIs) in patients receiving chronic hemodialysis through central venous catheters (HD-CVCs) |
globenewswire.com |
2024-10-24 12:30:00 |
Czytaj oryginał (ang.) |
| CorMedix Inc. to Report Third Quarter 2024 Financial Results and Provide a Corporate Update on October 30, 2024 |
BERKELEY HEIGHTS, N.J., Oct. 23, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that it will report its financial results for the third quarter ended September 30, 2024, before the market opens on Wednesday, October 30, 2024, and will host a corporate update conference call at 8:30am Eastern Time. |
globenewswire.com |
2024-10-23 12:30:00 |
Czytaj oryginał (ang.) |
| CorMedix Inc. to Present at the Cantor Global Healthcare Conference |
BERKELEY HEIGHTS, N.J., Sept. 13, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases, today announced that management will be participating in a fireside chat and investor meetings at the 2024 Cantor Healthcare Conference, being held in New York, NY on September 17 – 19, 2024. |
globenewswire.com |
2024-09-13 12:30:00 |
Czytaj oryginał (ang.) |
| Here's Why CorMedix (CRMD) Is a Great 'Buy the Bottom' Stock Now |
After losing some value lately, a hammer chart pattern has been formed for CorMedix (CRMD), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term. |
zacks.com |
2024-09-09 14:56:23 |
Czytaj oryginał (ang.) |
| CorMedix Inc. Announces New Commercial Agreement |
BERKELEY HEIGHTS, N.J., Sept. 09, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing therapeutic products for life-threatening diseases and conditions, today announced that it has entered into a multi-year commercial supply contract with a global healthcare company for the supply of DefenCath® (taurolidine and heparin) to its facilities in the US. |
globenewswire.com |
2024-09-09 14:52:00 |
Czytaj oryginał (ang.) |
| CorMedix (CRMD) Is Up 10.44% in One Week: What You Should Know |
Does CorMedix (CRMD) have what it takes to be a top stock pick for momentum investors? Let's find out. |
zacks.com |
2024-09-05 17:01:17 |
Czytaj oryginał (ang.) |